HEALTH● LOWOct 2 · Oct 2, 2026, 5:45 AM
19 . 3 % Weight Loss at Week 48 : Phase Ⅲ Data of Olatorepatide , Hansoh Dual ‑ Biased GLP ‑ 1 / GIP Agonist , Presented at EASD
prnewswire.com · United States · global
Phase III clinical trial data for Olatorepatide, a GLP-1/GIP agonist by Hansoh, showed significant weight loss at week 48 when presented at EASD. This represents a notable development in obesity treatment research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS3h agoHow Trump’s diesel deal with Russia will impact the United States and UkraineDW News [en]MILITARY3h agoStarlink signal cut: Ukraine under pressure from the United StatesLe Figaro InternationalPOLITICS12h agoOfficial and confirmed | The United States can deport foreigners who do not appear at the hearing with Form I-862ClarínPOLITICS1d agoEduardo Bolsonaro and Javier Milei to share an event in the United States, days before the runoff in Brazil and after an arrest warrant against himClarín
More in Health
HEALTH26m agoTrump’s CDC sending disease detective to Pennsylvania to help fight worst measles outbreak in 35 yearsThe Independent WorldHEALTH36m agoGood news for Parkinson's patients: a key remedy will be available again in NovemberClarínHEALTH1h agoA tooth grew in a teenager's eye and doctors removed it with surgery: the case that amazed world medicineClarínHEALTH1h agoFG releases ₦40.7 billion for primary healthcare, expands coverage to 13,000 facilitiesPremium Times